The report focuses on newer drugs and innovations in chemical compounds, vaccines and biologicals and diagnostic kits, recently launched or in development. Specifically excluded from the scope of research are vector or mosquito control approaches, strategies and products; drugs used for symptomatic treatment and not for the elimination of the virus from the host; and details on manufacturers and suppliers of non-branded generics.
The researchers have categorized the markets based on regions defined by the WHO since it is the primary organization mapping disease prevalence, assisting with access to medicine and enabling partnerships in a large number of infectious diseases. Regions include Africa, Americas, South-East Asia, Europe, Eastern Mediterranean and Western Pacific. These cover all the WHO participating countries, which are described in detail in the subsequent section.
- 84 data tables and 23 additional tables
- An overview of the global market for infectious disease treatments, with a focus on the growth in demand for newer pharmaceutical treatments, vaccines, and environmental products
- Analyses of global market trends with data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2022
- Discussion of the increasing concerns regarding antibiotic-resistant organisms and their sometimes-fatal effects on humans
- Examination of technological developments, future trends, and emerging opportunities
- Assessments of the current state of infectious diseases on a global basis, broken down by type of disease (i.e., bacterial, viral, parasitic, and fungal) and appropriate treatments, both current and anticipated, and by region
- Patent analyses
- Company profiles of major players in the market, including Alere (now Abbott), Novartis, Roche Diagnostics, Sanofi Pasteur and Siemens Healthineers
Infectious diseases are one of the major causes of global morbidity and mortality. Viral, bacterial, parasitic and fungal diseases have plagued humankind for centuries, and our attempts to control these diseases have met with great success. Diseases that were once death sentences are now either virtually eliminated or have become chronic, manageable diseases.
However, as with every ongoing story, microbes have transformed themselves to outwit current medications, and the battle to rid humans of the most virulent of diseases continues. With the constant combining and reinvention of microbes comes an urgent need for improved antibiotic and viral medications to sustain the progress made in addressing the most aggressive of infectious diseases.
Under these circumstances, there is need for a current and comprehensive report on infectious diseases covering diagnosis, treatment, demand trends, opportunities and emerging technologies. This study gives a clear, quantitative picture of the supply-and-demand scenario, and it highlights the technological and investment opportunities in the field.
Reasons For Doing The Study:
This report provides the reader with a detailed analysis of the global infectious disease market, with emphasis on seven major infectious diseases (i.e., human immunodeficiency virus/acquired immunodeficiency virus [HIV/AIDS]; hepatitis A, B, C; malaria, rotavirus/diarrhea; measles; pneumonia; and tuberculosis [TB]). These seven diseases account for 90% of infectious disease diagnoses. The report also discusses technological developments, future trends and emerging opportunities.
The major objectives of this study are:
- Assessing the current state of infectious diseases on a global basis.
- Identifying the driving factors for demand of new diagnostic and pharmaceutical products.
- Estimating current and future market sizes for diagnostic and pharmaceutical infectious disease products.
- Estimating the current global supply-and-demand scenario, by disease type and geographical regions.
- Identifying factors that influence the industry and proposing market opportunities.
- Alere (Now Abbott)
- Diasorin Spa
- Gilead Sciences
- Janssen, Pharmaceutical Company of Johnson & Johnson
- Medicines For Malaria Venture (Mmv)
- Orasure Technologies Inc.
- Roche Diagnostics
- Sanofi, Sanofi Pasteur
- Seqirus, a Csl Company
- Siemens Healthineers